Clinical Outcomes After Laparoscopic Antireflux Surgery in Patients with and Without Preoperative Endoscopic Esophagitis

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2003 Feb 1

PMID 12559184

Citations 11

Authors

Ketan M Desai

Margaret M Frisella

Nathaniel J Soper

Affiliations

Soon will be listed here.

Abstract

A wide spectrum of endoscopic findings exists in patients with gastroesophageal reflux disease (GERD). This study compared clinical outcomes after laparoscopic antireflux surgery (LARS) in patients who had GERD with and without preoperative endoscopic esophagitis. From 1992 to 2001, a total of 414 patients who underwent LARS with 6 months or more of follow-up were prospectively entered into a database. Among these patients, 84 (20%) had no endoscopic evidence of esophagitis on preoperative endoscopy (group 1), whereas 330 (80%) did have esophagitis (group 2). Perioperative outcomes, GERD symptom relief, and the use of acid-reducing medication were assessed. Preoperative DeMeester scores in groups 1 and 2 were 44 +/- 29 and 61 +/- 62 (P < 0.05) and mean esophageal peristaltic amplitude was 86 +/- 32 mm Hg vs. 60 +/- 42 mm Hg, respectively (P < 0.05). Although procedure time was significantly shorter in group 1, other perioperative outcomes were similar. At postoperative follow-up, the use of proton pump inhibitors was reduced in both groups (86% to < or =14%). With the exception of postoperative dysphagia, there was no difference in GERD symptom relief between groups 1 and 2. The presence or absence of preoperative esophagitis has minimal effect on favorable symptomatic outcomes after LARS. Thus LARS is an effective treatment option for patients, irrespective of endoscopic evidence of esophagitis, leading to excellent symptom relief and a marked reduction in the use of proton pump inhibitors.

Citing Articles

LAPAROSCOPIC REDO FUNDOPLICATION ALONE, REDO NISSEN FUNDOPLICATION, OR TOUPET FUNDOPLICATION COMBINED WITH ROUX-EN-Y DISTAL GASTRECTOMY FOR TREATMENT OF FAILED NISSEN FUNDOPLICATION.

Braghetto I, Korn O, Figueroa-Giralt M, Valenzuela C, Burgos A, Mandiola C Arq Bras Cir Dig. 2022; 35:e1678.

PMID: 36102488 PMC: 9462863. DOI: 10.1590/0102-672020220002e1678.

Preoperative Gastroesophageal Reflux Disorder Is Associated With Increased Morbidity in Patients Undergoing Abdominal Surgery.

Tilak A, Ramirez A, Turrentine F, Sohn M, Jones R J Surg Res. 2018; 232:587-594.

PMID: 30463778 PMC: 6251493. DOI: 10.1016/j.jss.2018.07.051.

Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease.

Park J, Chi K Ann Surg Treat Res. 2018; 95(2):94-99.

PMID: 30079326 PMC: 6073042. DOI: 10.4174/astr.2018.95.2.94.

Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors.

Tolone S, Gualtieri G, Savarino E, Frazzoni M, De Bortoli N, Furnari M World J Gastrointest Surg. 2016; 8(11):719-728.

PMID: 27933133 PMC: 5124700. DOI: 10.4240/wjgs.v8.i11.719.

Radiologic and endoscopic characteristics of laparoscopic antireflux wrap: correlation with outcome.

Braghetto I, Korn O, Csendes A, Valladares H, Davanzo C, Debandi A Int Surg. 2012; 97(3):189-97.

PMID: 23113845 PMC: 3723233. DOI: 10.9738/CC120.1.

References

Stein H, Eypasch E, DeMeester T, Smyrk T, Attwood S . Circadian esophageal motor function in patients with gastroesophageal reflux disease. Surgery. 1990; 108(4):769-77; discussion 777-8. View

Greason K, Miller D, Deschamps C, Allen M, Nichols 3rd F, Trastek V . Effects of antireflux procedures on respiratory symptoms. Ann Thorac Surg. 2002; 73(2):381-5. DOI: 10.1016/s0003-4975(01)03407-5. View

Galmiche J, Barthelemy P, Hamelin B . Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997; 11(4):765-73. DOI: 10.1046/j.1365-2036.1997.00185.x. View

Hunter J, Trus T, Branum G, Waring J, Wood W . A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg. 1996; 223(6):673-85; discussion 685-7. PMC: 1235211. DOI: 10.1097/00000658-199606000-00006. View

Bate C, Green J, Axon A, Murray F, Tildesley G, Emmas C . Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997; 11(4):755-63. DOI: 10.1046/j.1365-2036.1997.00198.x. View

Venables T, Newland R, Patel A, Hole J, Copeman M, Turbitt M . Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol. 1997; 32(7):627-32. DOI: 10.3109/00365529708996509. View

Joelsson B, Johnsson F . Heartburn--the acid test. Gut. 1989; 30(11):1523-5. PMC: 1434330. DOI: 10.1136/gut.30.11.1523. View

Watson R, Tham T, Johnston B, McDougall N . Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus". Gut. 1997; 40(5):587-90. PMC: 1027158. DOI: 10.1136/gut.40.5.587. View

Venables T, Newland R, Patel A, Hole J, Wilcock C, Turbitt M . Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997; 32(10):965-73. DOI: 10.3109/00365529709011211. View

10.

Achem S . Endoscopy-negative gastroesophageal reflux disease. The hypersensitive esophagus. Gastroenterol Clin North Am. 2000; 28(4):893-904, vii. DOI: 10.1016/s0889-8553(05)70096-0. View

11.

Eckardt V . Does healing of esophagitis improve esophageal motor function?. Dig Dis Sci. 1988; 33(2):161-5. DOI: 10.1007/BF01535727. View

12.

Spivak H, Smith C, Phichith A, Galloway K, Waring J, Hunter J . Asthma and gastroesophageal reflux: fundoplication decreases need for systemic corticosteroids. J Gastrointest Surg. 1999; 3(5):477-82. DOI: 10.1016/s1091-255x(99)80100-0. View

13.

Watson D, Foreman D, Devitt P, Jamieson G . Preoperative endoscopic grading of esophagitis versus outcome after laparoscopic Nissen fundoplication. Am J Gastroenterol. 1997; 92(2):222-5. View

14.

Soper N, Dunnegan D . Anatomic fundoplication failure after laparoscopic antireflux surgery. Ann Surg. 1999; 229(5):669-76; discussion 676-7. PMC: 1420811. DOI: 10.1097/00000658-199905000-00009. View

15.

Richter J, Kovacs T, Huang section sign B, Fisher R . Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999; 13(6):795-804. DOI: 10.1046/j.1365-2036.1999.00558.x. View

16.

Carlsson R, Holloway R . Endoscopy-negative reflux disease. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14(5):827-37. DOI: 10.1053/bega.2000.0127. View

17.

Watson D, Jamieson G . Antireflux surgery in the laparoscopic era. Br J Surg. 1998; 85(9):1173-84. DOI: 10.1046/j.1365-2168.1998.00829.x. View

18.

Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J . Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998; 10(2):119-24. View

19.

Clavien P, Sanabria J, Strasberg S . Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992; 111(5):518-26. View

20.

Lind T, Havelund T, Carlsson R, Glise H, Hernqvist H, Junghard O . Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32(10):974-9. DOI: 10.3109/00365529709011212. View